Antianginal and antihypertensive efficacy of calcium antagonist cardilopin in patients with coronary heart disease and arterial hypertension

Abstract

The authors studied antianginal and antihypertensive efficacy, safety, and quality of life influence, for a third-generation calcium antagonist, cardilopin (amlodipin; Egis, Hungary) inpatients with coronary heart disease (CHD) and arterial hypertension (AH). In total, 31 patients with stable angina pectoris, silent myocardial ischemia episodes, and associated AH, were examined. General clinic examination, 24-hour monitoring of blood pressure (BP) and ECG, veloergometry, quality of life assessment were performed. After 4 weeks of cardilopin therapy (mean daily dose 5. 5±0. 3 mg), weekly incidence of angina decreased by 52, 2 %, weekly nitroglycerine intake reduced by 54, 5 %, physical stress tolerance increased by 16, 7 %. Four-week cardilopin monotherapy (daily dose 5-10 mg) significantly reduced systolic and diastolic BP, day- and nighttime pressure load, and rate of diastolic BP morning increase in patients with mild to moderate AH, without affecting normal circadian BP rhythm and its variability. Therefore, cardilopin can be administered once per day, without adverse events in morning hours even among patients with riskfactors.